MEI Pharma To Consider Strategic Alternatives; Will Commence A Reduction-In-Force Beginning As Soon As Practicable And Continuing In Stages As The Co's Operational And Strategic Direction Evolves; Intends To Promptly Discontinue The Clinical...
MEI Pharma To Consider Strategic Alternatives; Will Commence A Reduction-In-Force Beginning As Soon As Practicable And Continuing In Stages As The Co's Operational And Strategic Direction Evolves; Intends To Promptly Discontinue The Clinical...
MEI Pharma To Consider Strategic Alternatives; Will Commence A Reduction-In-Force Beginning As Soon As Practicable And Continuing In Stages As The Co's Operational And Strategic Direction Evolves; Intends To Promptly Discontinue The Clinical Development Of Voruciclib
MEI Pharma將考慮戰略性選擇；將盡快開始並分階段進行裁員，以響應公司的運營和戰略方向的變化；打算迅速終止Voruciclib的臨床開發。
Company Commences a Cash Preservation Plan Including a Reduction in Force
公司啓動現金儲備計劃，包括裁員
MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process.
MEI Pharma，Inc.（NASDAQ：MEIP）（以下簡稱“公司”）今天宣佈，其董事會一致決定開始評估公司的戰略選擇，包括潛在交易以及有條不紊地關閉公司（如果適當的話），以最大化其資產對股東的價值。公司打算評估並聘請財務顧問以協助這一進程。
In order to best preserve the Company's existing cash, the Company will commence a reduction-in-force beginning as soon as practicable and continuing in stages as the Company's operational and strategic direction evolves. The Company intends to promptly discontinue the clinical development of voruciclib, while certain non-clinical activities related to MEI's drug candidate assets will continue to be conducted by the Company.
爲了最好地保留公司現有的現金，公司將盡快開始減少人員，並隨着公司的運營和戰略方向的演變而分階段進行。公司打算立即停止voruciclib的臨床開發，而涉及MEI候選藥物資產的某些非臨床活動將繼續由公司進行。